Xinli Shi | Tumor | Best Researcher Award

Posted on by Pencis

Ms. Xinli Shi | Tumor | Best Researcher Award

Shanxi University of Chinese Medicine | China

AUTHOR PROFILE

SCOPUS ID

ORCID ID

πŸ₯MS. XINLI SHI: ACADEMIC AND PROFESSIONAL PROFILE

πŸŽ“EARLY ACADEMIC PURSUITS

Ms. Xinli Shi, a Chinese national, began her academic journey with a B.Sc. in Biochemistry from the Department of Bioengineering at Hebei University of Science and Technology (1996–2001). She deepened her expertise in immunological mechanisms with an M.Sc. in Medical Immunology (2003–2007) from Hebei Medical University, followed by a Ph.D. in Immunology (2011–2014) from the West China College of Basic Medicine and Forensic Medicine, Sichuan Universityβ€”one of China’s top-tier medical schools.

🩺PROFESSIONAL ENDEAVORS

Prof. Shi’s academic career spans over two decades, reflecting progressive growth:

  • 2001–2013: She served at Hebei Medical University as a Teaching Assistant and then Lecturer, establishing foundational teaching experience.

  • 2013–2018: Appointed Associate Professor and Master’s Supervisor at the School of Basic Medicine, Hebei University of Chinese Medicine.

  • 2015–2017: Completed a Postdoctoral Fellowship at the Bethune International Peace Hospital, affiliated with the Third Military Medical University, focusing on advanced clinical research.

  • 2018–2023: Promoted to Professor and Doctoral Supervisor at Hebei University of Chinese Medicine.

  • 2023–Present: Serving as Professor and Doctoral/Master Supervisor at the Experimental Management Center, Shanxi University of Chinese Medicine.

πŸ”¬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR

Prof. Shi has made notable contributions in the field of tumor immunology, particularly within the tumor microenvironment, focusing on:

  • Autophagy

  • Drug Resistance

  • Restenosis

  • Inflammation-induced tumorigenesis

Her research explores how immune signaling and cellular stress responses shape tumor progression and therapeutic resistance, offering novel targets for immunomodulatory and chemotherapeutic interventions.

She has guided:

  • 3 Ph.D. students

  • 20+ M.D. students

  • Supervised postdoctoral fellows, actively fostering academic development and translational medicine research.

🌍IMPACT AND INFLUENCE

Prof. Shi’s work is highly regarded in both Western medicine and Traditional Chinese Medicine (TCM) circles. Her interdisciplinary approach integrates modern immunology with TCM principles, enabling translational applications in cancer and chronic disease therapy. She has been part of numerous provincial and national talent programs, contributing to science policy and medical education reform.

πŸ†RESEARCH GRANTS AND FUNDING

Prof. Shi has led 14 research projects, funded by prestigious national and provincial bodies. These include:

  • 2 National Natural Science Foundation of China (NSFC) grants (No. 81873112 & 82274315)

  • China Postdoctoral Science Foundation

  • Hebei Natural Science Foundation (multiple years)

  • Shanxi Science and Technology Department

  • Shanxi Provincial Administration of Traditional Chinese Medicine Innovation Team

πŸ”Ή Total grant portfolio spans over a decade, supporting basic, translational, and clinical research initiatives.

πŸ†LEGACY AND FUTURE CONTRIBUTIONS

Prof. Shi’s career exemplifies academic excellence, clinical relevance, and mentorship. With growing involvement in Shanxi’s TCM innovation programs, she is positioned to pioneer integrative oncology in Chinaβ€”blending evidence-based traditional practices with cutting-edge immunotherapy research. Her future directions include:

  • Building innovation teams

  • Leading multi-center translational studies

  • Expanding doctoral and postdoctoral programs

  • Enhancing international collaborations in cancer research

🧬CONCLUSION

Prof. Xinli Shi stands at the confluence of biochemistry, medical immunology, and TCM oncology, with over 20 years of academic and clinical experience. Her dedication to tumor biology, immune modulation, and interdisciplinary research continues to shape the landscape of cancer therapeutics in China. As a mentor, scholar, and innovator, she contributes profoundly to the development of next-generation scientists and the advancement of personalized medicine.

πŸ“ŠπŸ”¬NOTABLE PUBLICATION:

RalB promotes lymph node metastasis in tongue squamous cell carcinoma

Authors: Y. Zhang, Yuman; Z. Liu, Zhihan; Y. Yang, Yanguang; L. Jia, Lifeng; X. Shi, Xinli
Journal: Genes and Genomics
Year: 2025

Human umbilical cord mesenchymal stem cells promoted tumor cell growth associated with increased interleukin-18 in hepatocellular carcinoma

Authors: Y. Yang, Yanguang; S. Li, Shenghao; Q. Peng, Qing; Y. Zhang, Yuman; X. Shi, Xinli
Journal: Molecular Biology Reports
Year: 2024

Recent advances in graphitic carbon nitride-based heterojunction for biomedical applications

Authors: R. Jia, Ruilong; C. He, Cheng’en; S. Wang, Shanshan; G. Liao, Guangfu; X. Shi, Xinli
Citations: 3

Di Fan | Molecular Imaging in Drug Development | Best Researcher Award

Posted on by Pencis

Ms. Di Fan | Molecular Imaging in Drug Development | Best Researcher Award

Capital Medical University | China

AUTHOR PROFILE

Scopus

πŸ“Œ DI FAN, PhD

Associate Researcher
Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University

πŸŽ“ EDUCATION AND EARLY ACADEMIC PURSUITS

Di Fan pursued his Bachelor’s degree at Wuhan University (2006-2010), where he built a strong foundation in biomedical sciences. His passion for advanced medical research led him to Peking University (2010-2015), where he obtained his PhD. During his doctoral studies, he focused on radiopharmaceuticals and molecular imaging, setting the stage for a career dedicated to cutting-edge advancements in nuclear medicine.

πŸ₯ PROFESSIONAL ENDEAVORS

Currently serving as an Associate Researcher at the Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Di Fan plays a pivotal role in advancing molecular imaging and targeted cancer therapies. His work bridges the gap between innovative radiopharmaceuticals and their clinical applications, contributing to the early detection and treatment of cancer.

πŸ”¬ CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Fan’s research is primarily focused on:

  • Radiopharmaceutical Development – Designing novel radioactive tracers for precise cancer imaging and treatment.
  • Molecular Imaging – Utilizing advanced PET and SPECT imaging techniques to enhance tumor detection and therapeutic monitoring.
  • Targeted Cancer Therapy – Developing radiolabeled compounds to selectively attack cancer cells, minimizing damage to healthy tissues.

His work contributes significantly to improving personalized cancer treatment, ensuring higher accuracy in diagnosis and therapy.

🌍 IMPACT AND INFLUENCE

Dr. Fan’s contributions have been recognized through numerous scientific publications, collaborations with leading medical institutions, and participation in national and international research projects. His expertise in nuclear medicine and molecular imaging has influenced both clinical practices and medical innovations in China and beyond.

πŸ“š ACADEMIC CITES AND RECOGNITION

  • Published extensively in high-impact SCI-indexed journals related to radiopharmaceuticals and cancer imaging.
  • H-index and citations reflect his significant contribution to the field of nuclear medicine.
  • Regularly invited to present at global medical and radiology conferences, sharing insights on novel imaging techniques.

πŸš€ LEGACY AND FUTURE CONTRIBUTIONS

Dr. Fan aims to:
βœ… Develop next-generation radiopharmaceuticals for better cancer detection and treatment.
βœ… Strengthen collaborations between academic and clinical institutions to enhance nuclear medicine applications.
βœ… Advance precision oncology, integrating AI-driven analysis for personalized cancer therapies.

His research will continue shaping the future of molecular imaging and targeted therapies, ensuring breakthroughs in early cancer diagnosis and patient-centered treatments.

🧬CONCLUSION

Dr. Di Fan stands at the forefront of nuclear medicine research, making significant strides in radiopharmaceuticals, molecular imaging, and targeted cancer therapy. His dedication to scientific innovation and clinical application has not only enhanced cancer diagnostics and treatment but also paved the way for more effective and personalized medical approaches.

 

πŸ“ŠπŸ”¬NOTABLE PUBLICATION:
    1. Title: Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse Models
      Authors: D., Fan, Di , X., Wang, Xin , X., Ling, Xueyuan , … Z., Wu, Zehui , L., Ai, Lin
      Journal: Pharmaceuticals
      Year: 2025

Prof. Linghua Li | Cancer Science | Best Researcher Award

Posted on by Pencis

Prof. Linghua Li | Cancer Science | Best Researcher Award

Guangzhou Eighth People’s Hospital | China

Author Profile

ORCID ID

🌟Linghua Li, Ph.D., M.S., B.S. 🌍

Head Director, Infectious Disease Center
Guangzhou Eighth People’s Hospital, Guangzhou Medical University

πŸ‘©β€βš•οΈBiography

Dr. Linghua Li is a distinguished physician and researcher specializing in HIV/AIDS, infectious diseases, and oncology. With over 25 years of clinical experience, she has made significant contributions to understanding and managing infectious diseases, particularly fungal infections and HIV-related complications.

Dr. Li began her academic journey at the Medical School of Peking University, earning a B.S. in Clinical Medicine in 1997. She then pursued advanced studies at Sun Yat-sen University, completing an M.S. in Internal Medicine in 2008 and a Ph.D. in Infectious Diseases in 2011. She further enriched her expertise through visiting scholar positions at UNC-Chapel Hill (2012) and Duke University (2014), focusing on infectious diseases.

As the Head Director of the Infectious Disease Center at Guangzhou Eighth People’s Hospital, Dr. Li oversees clinical trials, patient care, and research initiatives for people living with HIV and at-risk populations. She has been principal investigator (PI) or co-investigator (Co-I) on more than 20 domestic and international research programs. Notable projects include:

  • National Natural Science Foundation of China (Grant No. 81301480): Investigating the mechanism and function of Phospholipase B in the growth and pathogenicity of P. marneffei.
  • Guangdong Natural Science Foundation (Grant No. 10151006002000000): Exploring the role of Phospholipase B in P. marneffei invasion of macrophages in AIDS patients.
  • NIH Fogarty Program: Examining host factors in severe opportunistic complications of AIDS, with a focus on developing targeted prophylactic strategies.

In recent years, Dr. Li has been a Co-PI on groundbreaking HIV PrEP Phase IV clinical trials in Guangzhou, including:

  • ChiCTR2100048981 and NCT04754139: These studies focus on scaling PrEP access for key populations in China. The trial successfully enrolled 1,007 participants by 2023, with 950 already on PrEP, marking it as the largest trial of its kind in China.

Dr. Li’s work emphasizes translational medicine, data-driven public health strategies, and the implementation of novel interventions like PrEP to curb HIV transmission. Her expertise in site coordination, implementation, data collection, and analysis has been pivotal to these efforts.

🧬Key Areas of Expertise

πŸ”¬ HIV Prevention and Treatment
🌿 Opportunistic Infections
πŸ“Š Clinical Trials and Data Analysis
πŸ§‘β€βš•οΈ Internal and Infectious Diseases

πŸ“šAcademic Background

  • B.S., Clinical Medicine, Medical School of Peking University (1997)
  • M.S., Internal Medicine, Sun Yat-sen University (2008)
  • Ph.D., Infectious Diseases, Sun Yat-sen University (2011)
  • Visiting Scholar, UNC-Chapel Hill (2012)
  • Visiting Scholar, Duke University (2014)

πŸ”¬Research Impact

🌟 Over 20 funded research projects
πŸ“„ Numerous publications in infectious disease and public health journals
πŸ“š Active contributor to advancing HIV prevention strategies in China

Dr. Linghua Li remains a leader in the fight against infectious diseases, with a career dedicated to improving global health outcomes. 🌏✨

✨ Conclusion

Dr. Linghua Li’s career exemplifies dedication to advancing the prevention, treatment, and understanding of infectious diseases, particularly HIV/AIDS and associated complications. Through her leadership, innovative research, and clinical expertise, she has significantly impacted global health, especially in developing effective interventions like PrEP for key populations in China. Her contributions to translational medicine and public health continue to pave the way for breakthroughs in managing infectious diseases and improving the lives of those affected worldwide. 🌟🌍

πŸ“ŠπŸ”¬NOTABLE PUBLICATION:
  • Utilizing Protein–Peptide Hybrid Microarray for Time-Resolved Diagnosis and Prognosis of COVID-19
    • Authors: Peiyan Zheng, Baolin Liao, Jiao Yang, Hu Cheng, Zhangkai Cheng, Huimin Huang, Wenting Luo, Yiyue Sun, Qiang Zhu, Yi Deng, et al.
    • Journal: Microorganisms
    • Year: 2023

Mr. Toshitaka Hirano | Malignancy | Best Researcher Award

Posted on by Pencis

Mr. Toshitaka Hirano | Malignancy | Best Researcher Award

Pfizer Japan Inc | Japan

AUTHOR PROFILE

ORCID ID

🏫 EARLY ACADEMIC PURSUITS

Mr. Toshitaka Hirano pursued his education in Japan, specializing in fields related to oncology and pharmaceutical sciences. His early academic years were marked by a strong commitment to understanding the mechanisms of malignancy and its risk factors, laying the foundation for his influential career.

πŸ’Ό PROFESSIONAL ENDEAVORS

Currently associated with Pfizer, Mr. Hirano has established himself as a leading expert in the risk factor analysis of malignancy. His role includes conducting advanced research, collaborating with global teams, and integrating pharmaceutical innovation with clinical practice.

🧬 CONTRIBUTIONS AND RESEARCH FOCUS

Mr. Hirano’s research is focused on identifying malignancy risk factors, particularly in patients with chronic conditions like rheumatoid arthritis. His studies examine the interplay between biological, environmental, and genetic factors contributing to cancer development. He has significantly advanced understanding in areas such as:

  • Immunogenicity risk associated with biologics
  • Cardiovascular events in rheumatic disease patients
  • Safety and effectiveness of novel therapies like tofacitinib

🌏 IMPACT AND INFLUENCE

Mr. Hirano’s work has had a profound impact on both clinical and research landscapes:

  • Policy and Practice: His findings inform public health guidelines and pharmaceutical strategies.
  • Patient Outcomes: Through his research, he has contributed to safer and more effective treatments for vulnerable populations.
  • International Collaboration: His global outreach ensures the dissemination of knowledge and best practices.

πŸ“š ACADEMIC CITES

Mr. Hirano’s scholarly work is widely cited in high-impact journals, demonstrating its relevance and importance. Key publications include articles in International Journal of Rheumatic Diseases, Frontiers in Immunology, and Modern Rheumatology, highlighting his expertise in malignancy risk within rheumatic populations.

πŸ† LEGACY AND FUTURE CONTRIBUTIONS ON MALIGNANCY

As a trailblazer in the field, Mr. Hirano is building a legacy of innovation and dedication to improving cancer outcomes. His future efforts aim to:

  • Develop predictive models for malignancy risks.
  • Enhance personalized medicine approaches.
  • Mentor the next generation of researchers in oncology and pharmaceutical sciences.

πŸ“Œ OTHER IMPORTANT TOPICS

πŸ” INTERDISCIPLINARY INTEGRATION

Mr. Hirano’s work bridges multiple fields, including oncology, immunology, and rheumatology, showcasing the value of a holistic research approach.

🌟 MENTORSHIP AND TEAM LEADERSHIP

He plays an active role in guiding young researchers and fostering collaborative environments that drive innovation.

πŸ”” PATIENT-CENTERED FOCUS

By emphasizing real-world data and patient-centered outcomes, Mr. Hirano ensures his work directly benefits those in need.

✨ CONCLUSION

Mr. Toshitaka Hirano’s dedication to malignancy risk analysis exemplifies the power of focused research to drive meaningful change. His work at Pfizer and beyond demonstrates a commitment to innovation, collaboration, and improving global health. With a legacy rooted in impactful research and a vision for a healthier future, Mr. Hirano continues to inspire and lead in the fight against cancer.

πŸ“ŠπŸ”¬NOTABLE PUBLICATION:
  • 1️⃣ Risk Factors Associated With Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis in a Real-World Setting in Japan
    • Authors: Kunihiro Yamaoka, Sugiyama N, Hoshi M, Jo JY, Kichul Shin, Hirano T
    • Journal: International Journal of Rheumatic Diseases
    • Year: 2024

    2️⃣ Individual and Population-Level Variability in HLA-DR Associated Immunogenicity Risk of Biologics Used for the Treatment of Rheumatoid Arthritis

    • Authors: Sugiyama N, Terry FE, Gutierrez AH, Hirano T, Hoshi M, Mizuno Y, Martin W, Yasunaga S, Niiro H, Fujio K, et al.
    • Journal: Frontiers in Immunology
    • Year: 2024

    3️⃣ Six-Month Safety and Effectiveness of Tofacitinib in Patients With Rheumatoid Arthritis in Japan: Interim Analysis of Post-Marketing Surveillance

    • Authors: Masataka Kuwana, Sugiyama N, Momohara S, Atsumi T, Takei S, Naoto Tamura, Masayoshi Harigai, Fujii T, Matsuno H, Takeuchi T, et al.
    • Journal: Modern Rheumatology
    • Year: 2024

Prof. Huaiqing Lv | Neck Tumors | Best Researcher Award

Posted on by Pencis

Prof. Huaiqing Lv | Neck Tumors | Best Researcher Award

Shandong Second Medical University | China

Author Profile

Scopus

🌟 Dr. Lv Huaiqing, M.D.

Chief Physician & Master’s Degree Supervisor

Director of Otorhinolaryngology & Head and Neck Surgery

Linyi People’s Hospital, Shandong Province

πŸ‘©β€βš•οΈ Professional Summary:

Dr. Lv Huaiqing is a distinguished Chief Physician and subject leader at Linyi People’s Hospital, specializing in Otorhinolaryngology and Head and Neck Surgery. With extensive experience in clinical practice and research, Dr. Lv has significantly contributed to the field through her leadership roles and numerous scientific projects.

**🌐 Part-Time Roles:

  • Vice Chairman, Otorhinolaryngology, Head and Neck Surgery Committee, Shandong Provincial Medical Association
  • Vice Chairman, Hearing and Balance Medical Association, Shandong Provincial Medical Association
  • Member, Voice Committee, Otorhinolaryngology Committee, Chinese Association of Integrative Medicine
  • Standing Member, Head and Neck Tumor Committee, China Medical Education Association
  • Vice Chairman, Ear, Nose and Throat Committee, Shandong Association of Integrative Medicine
  • Vice Chairman, Pharyngeal, Head and Neck Surgery Committee, Shandong Provincial Association of Health Management
  • Director, Linyi Otorhinolaryngology Quality Control Center
  • Linyi Health Leader
  • Director, Otolaryngology Branch, Linyi Physicians Association

πŸ“š Research Contributions:

Dr. Lv has authored 13 papers as the first author or corresponding author in the past year. She has presided over 3 provincial and municipal level projects, including:

  • Application of Posterior Auricular Groove Incision in Surgery of Benign Tumor of Parotid Gland
  • Evaluation of Orbital Invasion of Sinus Tumor Based on CT, MRI, and Machine Learning Models
  • Posterior Auricular Groove Incision in Surgery of Benign Tumor of Superficial Parotid Gland

Her research has received significant funding of 400,000 RMB and has led to several municipal science and technology awards. The research team excels in various methods, including bioinformatics, meta-analysis, and machine learning predictive models.

πŸŽ“ Teaching Commitment:

Currently, Dr. Lv supervises Master’s degree students at Qingdao University, Shandong Second Medical University, and Binzhou Medical College, having guided 10 students to date.

πŸ”¬ Current Publications:

She is also the first author or corresponding author of approximately 20 newly accepted and submitted articles in Chinese core or SCI journals.

Dr. Lv Huaiqing’s dedication to otorhinolaryngology, combined with her commitment to research and education, makes her a leading figure in her field.

πŸ”” Conclusion

Dr. Lv Huaiqing stands out as a prominent leader in Otorhinolaryngology and Head and Neck Surgery, with a rich background in clinical practice, research, and education. Her extensive involvement in various medical associations and committees demonstrates her commitment to advancing the field and enhancing patient care. Through her innovative research projects and dedication to mentoring future healthcare professionals, Dr. Lv continues to make significant contributions to medical science and the development of her specialty in Shandong Province and beyond.

πŸ“ŠπŸ”¬NOTABLE PUBLICATION:

    • Circ_0058124 upregulates MAPK1 expression to promote proliferation, metastasis and metabolic abilities in thyroid cancer through sponging miR-940
      • Authors: Sun, D., Chen, L., Lv, H., Liu, X., Zhang, X.
      • Journal: OncoTargets and Therapy
      • Year: 2020

     

    • Predicting biomarkers in laryngeal squamous cell carcinoma based on the cytokine-cytokine receptor interaction pathway
      • Authors: Chen, Q., Wang, D., Chen, Z., Li, P., Lv, H.
      • Journal: Heliyon
      • Year: 2024

     

    • Genetically predicted allergic rhinitis causally increases the risk of erectile dysfunction
      • Authors: Li, P., Meng, Z., Lin, L., Chen, Z., Lv, H.
      • Journal: Frontiers in Genetics
      • Year: 2024

     

    • A novel frameshift mutation of the endoglin (ENG) gene causes hereditary hemorrhagic telangiectasia in a Chinese family
      • Authors: Li, P., Gao, C., Wei, Y., Shao, Q., Lv, H.
      • Journal: European Archives of Oto-Rhino-Laryngology
      • Year: 2024

     

    • Upregulation of microRNA-141 suppresses epithelial-mesenchymal transition and lymph node metastasis in laryngeal cancer through HOXC6-dependent TGF-Ξ² signaling pathway
      • Authors: Chen, L., Sun, D.-Z., Fu, Y.-G., Gao, Y., Zhang, X.-Y.
      • Journal: Cellular Signalling
      • Year: 2020

Prof. Hongsheng Liu | Pharmaco-Oncology | Best Researcher Award

Posted on by Pencis

Prof. Hongsheng Liu | Pharmaco-Oncology | Best Researcher Award

Liaoning University | China

Author Profile

Scopus

🌟 Professor Hongsheng Liu: A Pioneer in Microbiology and Bioinformatics

Professor, School of Pharmaceutical Sciences, Liaoning University, China

πŸ”¬ Academic and Professional Background

Professor Hongsheng Liu obtained a Master’s degree in Microbiology from China Agricultural University in 1991 and later pursued a Ph.D. in Microbiology and Bioinformatics at Gifu University School of Medicine, Japan, in 2004. Over the years, he has expanded his expertise by serving as a visiting scholar at prestigious institutions such as Wuhan University, the University of Hong Kong, Harvard Medical School, and Hebrew University of Jerusalem. His career reflects a deep commitment to advancing the fields of microbiology, bioinformatics, and pharmaceutical sciences.

πŸ’‘ Research and Innovations

Professor Liu has completed an impressive 74 research projects and authored over 100 journal articles (SCI, Scopus, etc.), accumulating a citation index of 2721. His work spans diverse areas, including the discovery of the novel microorganism Paenibacillus liaoningensis sp. nov. and the investigation of influenza virus interactions. His contributions to computational biology include the development of several predictive algorithms and online platforms like CarcinoPred-EL and LiverToxPred-EL. Additionally, Professor Liu holds 37 patents, has published 4 books, and has led 7 industry consultancy projects.

πŸ“š Published Works and Collaborations

Professor Liu’s collaborative research includes partnerships with renowned institutions such as the University of Toledo, Harvard Medical School, and Eberhard Karl University of TΓΌbingen. He has also served as a guest editor for Frontiers in Microbiology (2017-2018). His dedication to both basic and applied research continues to push the boundaries of pharmaceutical sciences.

πŸ‘₯ Professional Memberships

He is an active member of the Chinese Society for Microbiology (CSM) and the Chinese Chemical Society (CCS).

🌍 Areas of Research

Professor Liu specializes in computer-aided drug design and the simulation of biomacromolecule interactions, with a focus on studying lncRNAs and disease relationships, and designing stable recombinant proteins using engineered bacteria.

πŸ”” Conclusion

Professor Hongsheng Liu stands as a distinguished leader in microbiology and bioinformatics, contributing significantly to drug design, biomolecular simulation, and microbial discovery. His broad academic collaborations, cutting-edge innovations, and vast research output underscore his influence in the scientific community. Through his extensive work on predictive algorithms, microbial databases, and recombinant protein design, he has made impactful advancements in pharmaceutical sciences. With over 100 journal publications, 37 patents, and numerous prestigious collaborations, Professor Liu’s dedication to advancing scientific knowledge and improving human health is truly commendable.

πŸ“ŠπŸ”¬NOTABLE PUBLICATION:

    • Article Title: Ensemble multiclassification model for aquatic toxicity of organic compounds
      Authors: Li, X., Liu, G., Wang, Z., Liu, H., Ai, H.
      Journal: Aquatic Toxicology
      Year: 2023

     

    • Article Title: Construction of an oxidative stress-related lncRNAs signature to predict prognosis and the immune response in gastric cancer
      Authors: Zhang, H., Feng, H., Yu, T., Ma, L., Liu, H.
      Journal: Scientific Reports
      Year: 2023

     

    • Article Title: CBIL-VHPLI: a model for predicting viral-host protein-lncRNA interactions based on machine learning and transfer learning
      Authors: Zhang, M., Zhang, L., Liu, T., Zhao, J., Liu, H.
      Journal: Scientific Reports
      Year: 2024

     

    • Article Title: Construction of highly active and stable recombinant nattokinase by engineered bacteria and computational design
      Authors: Wang, L., Meng, J., Yu, X., Zhang, L., Liu, H.
      Journal: Archives of Biochemistry and Biophysics
      Year: 2024

     

    • Article Title: Effects of dietary supplementation of gallic tannic acid on growth, intestinal digestive enzymes activity, innate immunity, morphology, and microbial composition of Cyprinus carpio
      Authors: Feng, H., Zhao, S., Ma, X., Liu, Z., Liu, H.
      Journal: Aquaculture International
      Year: 2024

Assist Prof Dr Mohamed Lemine Cheikh Brahim Ahmed | HPV | Best Researcher Award

Posted on by Pencis

Assist Prof Dr Mohamed Lemine Cheikh Brahim Ahmed | HPV | Best Researcher Award

University of Nouakchott | Mauritania

Author Profile

Scopus

ORCID ID

Dr. Mohamed Lemine Cheikh Brahim Ahmed

πŸŽ“Education :

  • PhD in Public Health 🧬
    UniversitΓ© Mohammed V, Rabat, Morocco
  • Master of Public Health in Molecular Epidemiology of Zoonotic Diseases πŸ¦ πŸ”¬
    IAV Hassan II, Rabat, Morocco
  • Certificate in Molecular Biology and Bioinformatics πŸ§¬πŸ’»
    Hua Zhong Normal University, Wuhan, China

🌍Professional Memberships :

  • Member of the World Society for Virology (WSV) 🧫
  • Member of the International Covid-19 Research Network (ICRN) 🦠
  • Member of the One Health Heukelbach Institute 🌱
  • Member of the MENA Coalition for HPV Elimination πŸ’‰
  • Member of the Research Unit on Molecular Epidemiology and Microorganism Diversity (EMDM) 🧬
  • President of the Mauritanian Society for Scientific Research (AMDRS) πŸ§‘β€πŸ”¬
  • Collaborator on the Global Burden of Diseases (GBD) project, Institute for Health Metrics and Evaluation, University of Washington 🌎

πŸ’‘Key Skills :

  • Vaccine Coordination & Logistics πŸššπŸ’‰:

  • Planned and supervised vaccine logistics for remote regions in Mauritania, ensuring stock management and quality control practices for vaccines like PCV13 and Rotarix.

  • Public Health Communication & Training πŸ“’πŸ‘©β€βš•οΈ:

  • Conducted team-building and training sessions for local health personnel, focusing on routine and Covid-19 vaccination campaigns.

  • Research Project Management πŸ§‘β€πŸ”¬πŸ“Š:

  • Led public health research projects, managing performance indicators, and reporting on vaccine distribution and health systems.

  • Flexibility & Versatility βš™οΈ:

  • Adapted to various challenges in vaccine distribution and epidemiological surveillance, especially during pandemics.

βœ…Main Qualifications :

Vaccination πŸ’‰:

  • Supervised and trained local teams for stock management and quality control of vaccines across remote areas in Mauritania.
  • Led national Covid-19 vaccination strategy development, training teams and evaluating the impact of vaccine introductions (e.g., PCV13, Rotarix).
  • Coordinated routine vaccination campaigns across all 15 regions of Mauritania and introduced critical vaccines like nVPO2 for polio.

Epidemiological Surveillance 🧬:

  • Developed and implemented national strategies for combatting Covid-19, including plans for testing diseases like measles, polio, hemorrhagic fevers, and HPV.
  • Organized and led sentinel surveillance programs for diseases like rotavirus and influenza.
  • Conducted performance evaluations of Mauritania’s health information systems and trained response teams for integrated epidemiological surveillance.

🏒Recent Professional Experience :

National Consultant

UNICEF, Mauritania (Feb 2022 – Jul 2022)
Supported cold chain logistics and vaccine management for poliomyelitis response campaigns. Key tasks included overseeing vaccine distribution, supporting data analysis, and participating in meetings for budget planning with GPEI.

  • Provided technical assistance for vaccine logistics, ensuring the collection and destruction of unusable vaccine vials.
  • Led training sessions for independent monitors and LQAS surveyors to evaluate the polio vaccination campaign.

πŸ“ˆ Conclusion🌟

Dr. Mohamed Lemine Cheikh Brahim Ahmed is a highly skilled expert in vaccination logistics and epidemiological surveillance πŸ¦ πŸ’‰, with extensive experience in public health, research management, and disease control. His work spans from developing national vaccination strategies, including Covid-19, to training teams and overseeing campaigns in remote regions of Mauritania. As a member of numerous global health organizations 🌍 and a key contributor to projects like the Global Burden of Diseases 🌎, he is committed to improving public health outcomes through innovative approaches and evidence-based strategies. Dr. Ahmed’s versatility, leadership, and dedication make him a valuable asset in the field of global health and vaccination efforts.

πŸ“ŠπŸ”¬NOTABLE PUBLICATION:

 

    • Article: Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017
      • Authors: Troeger, C.E., Khalil, I.A., Blacker, B.F., Hay, S.I., Reiner, R.C.
      • Journal: The Lancet Infectious Diseases
      • Year: 2020

     

    • Article: Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017
      • Authors: Troeger, C.E., Khalil, I.A., Blacker, B.F., Hay, S.I., Reiner, R.C.
      • Journal: The Lancet Infectious Diseases
      • Year: 2020

     

    • Article: The global case fatality rate of coronavirus disease 2019 by continents and national income: A meta-analysis
      • Authors: Abou Ghayda, R., Lee, K.H., Han, Y.J., Smith, L., Shin, J.I.
      • Journal: Journal of Medical Virology
      • Year: 2022

     

    • Article: Nonpharmaceutical interventions reduce the incidence and mortality of COVID-19: A study based on the survey from the International COVID-19 Research Network (ICRN)
      • Authors: Park, S.H., Hong, S.H., Kim, K., Il Shin, J., Smith, L.
      • Journal: Journal of Medical Virology
      • Year: 2023

     

    • Article: COVID-19 outbreak in Mauritania: Epidemiology and health system response
      • Authors: Ahmed, M.L.C.B., Zehaf, S., El Alem, M.M., Abdellahi, M.V.M., Heukelbach, J.
      • Journal: Journal of Infection in Developing Countries
      • Year: 2021

Dr. Abdulhadi Aljawish | Cytotoxicity | Best Researcher Award

Posted on by Pencis

Dr. Abdulhadi Aljawish | Cytotoxicity | Best Researcher Award

National Conservatory of Arts and Crafts | France

Author Profile

Scopus

Google Scholar

Biography: Dr. Abdulhadi ALJAWISH

πŸ§‘β€πŸ”¬ Education

2009-2013: Ph.D. in Biotechnological and Food Processes (with Honors)
Laboratoire d’IngΓ©nierie des BiomolΓ©cules-ENSAIA, UniversitΓ© de Lorraine, Nancy, France
Thesis: “Enzymatic functionalization of chitosan with phenolic compounds by Myceliophthora thermophila laccase”
Advisors: Prof. JoΓ«l SCHER, Prof. Isabelle CHEVALOT
Defense Date: 08/07/2013

2008-2009: Master’s in Biotechnology, Agro-resources, Food, Nutrition (B.A.A.N) (with Merit)
Laboratoire de Biocatalyse-BioprocΓ©dΓ©s (LBB), ENSAIA-INPL, Nancy, France
Research: “Enzymatic synthesis of natural colorants from phenolic compounds”
Advisors: Prof. Michel GIRARDIN, Dr. Lionel MUNIGLIA

πŸ‘¨β€πŸ’Ό Professional Experience

2021-2023: Head of Research & Development in Enzymatic Processes
SAS GECCO, Institut Charles VIOLLETTE – Laboratoire des ProcΓ©dΓ©s Biologiques, GΓ©nie Enzymatique et Microbien (ProBioGem), UniversitΓ© de Lille, Lille, France

2019-2021: Research & Development Engineer in Enzymatic Processes
SAS GECCO, Institut Charles VIOLLETTE – Laboratoire des ProcΓ©dΓ©s Biologiques, GΓ©nie Enzymatique et Microbien (ProBioGem), UniversitΓ© de Lille, Lille, France

2016-2018: Postdoctoral Fellow in Biocatalysis – Bioprocesses
Institut Charles VIOLLETTE – Laboratoire des ProcΓ©dΓ©s Biologiques, GΓ©nie Enzymatique et Microbien (ProBioGem), UniversitΓ© de Lille, Lille, France

2015-2016: Postdoctoral Fellow in Biochemistry – Toxicology
Institut de Chimie MolΓ©culaire (ICMUB-UMR-CNRS6302), UniversitΓ© de Bourgogne, Dijon, France
Laboratoire de Nutrition et Toxicologie (NuTox), INSERM -UMR U866-Agrosup, Dijon, France

2013-2015: Temporary Teaching and Research AttachΓ© (ATER) in Biochemistry – Food Biotechnology
Γ‰cole nationale supΓ©rieure d’agronomie et des industries alimentaires (ENSAIA), UniversitΓ© de Lorraine, Nancy, France

2009-2013: Ph.D. Researcher in Biotechnology and Food Processes
Laboratoire d’IngΓ©nierie des BiomolΓ©cules (LIBio), Laboratoire RΓ©actions et GΓ©nie des procΓ©dΓ©s (LRGP)-ENSAIA, UniversitΓ© de Lorraine, Nancy, France

πŸ“š Supervision and Collective Responsibilities

  • Supervised several Master’s and Ph.D. students in various projects related to enzymatic purification, functionalization, and biotests development.
  • Managed projects on the valorization of food waste and biodiesel by-products, emphasizing circular economy principles.

🧬 Skills and Expertise

  • Circular Economy: Valorization of food waste and biomass, biodiesel production, energy recovery.
  • Biosynthesis/Biocatalysis: Enzyme purification and characterization, oxidative processes, esterification, transesterification, kinetic studies, various enzymes like lipase, polyphenol oxidases, cellulase, amidase, and decarboxylase.
  • Structural Characterization: UV-Vis spectroscopy, HPLC, LC-MS, GC-MS, FT-IR, NMR.
  • Industrial Processes: Extraction, purification, separation, sterilization, pasteurization, atomization, evaporation, lyophilization.
  • Physicochemical Properties: Particle size, color parameters, viscosity, thickness, zeta potential, melting and boiling points, colloidal stability, water sorption isotherms, thermal properties.
  • Biochemistry: Antioxidant tests, microbiological assays, cell culture, cytotoxicity, genotoxicity, biocompatibility, polymer chemistry, food analysis.
  • Technical Skills: Expertise with various analytical instruments and techniques, including FT-IR, NMR, HPLC, LC-MS, SEM, TEM, and many others.
  • Statistical Analysis: ANOVA, Duncan’s Multiple Range tests.
  • Certifications: Management, Biotechnology, Life Cycle Analysis (SimaPro).

🌐 Language and Computer Proficiency

  • Languages:
    • French (Fluent)
    • English (Fluent)
    • Arabic (Native)
  • Computer Skills:
    • Microsoft Office (Word, Excel, PowerPoint)

This summary encapsulates the academic and professional journey of Abdulhadi ALJAWISH, emphasizing his vast experience in biotechnological processes, food science, and enzymatic applications.

 

πŸ“ŠπŸ”¬Notable Publication:

 

  • Bioprocesses for the Biodiesel Production from Waste Oils and Valorization of Glycerol
    • Authors: Decarpigny, C., Aljawish, A., His, C., Millares, M., Froidevaux, R.
    • Journal: Energies
    • Year: 2022

 

  • Green synthesis of glyco-phenol by enzymatic coupling between ferulic acid and glucosamine: An ecofriendly procedure
    • Authors: Aljawish, A., Chevalot, I., Paris, C., Muniglia, L.
    • Journal: Biotechnology and Applied Biochemistry
    • Year: 2022

 

  • Enzymatic Oxidation of Ferulic Acid as a Way of Preparing New Derivatives
    • Authors: Aljawish, A., Chevalot, I., Paris, C., Muniglia, L.
    • Journal: BioTech
    • Year: 2022

 

  • Comparing the efficiency of extracting antioxidant polyphenols from spent coffee grounds using an innovative ultrasound-assisted extraction equipment versus conventional method
    • Authors: Beaudor, M., Vauchel, P., Pradal, D., Aljawish, A., Phalip, V.
    • Journal: Chemical Engineering and Processing – Process Intensification
    • Year: 2023

 

  • Synthesis and characterization of release agent from used cooking oil at the concrete/formwork interface
    • Authors: Libessart, L., Anceur, R., Djelal, C., Aljawish, A., Millares, M.
    • Journal: International Journal of Environmental Science and Technology
    • Year: 2023

Prof. Elina Genina | Tumor Model | Best Researcher Award

Posted on by Pencis

Prof. Elina Genina | Tumor Model | Best Researcher Award

Saratov State University | Russia

Author Profile

Scopus

Orcid id

Google Scholar

πŸ“š Biography: Prof. Elina A. Genina

  • πŸŽ“ Education:

    • Saratov State University, Saratov, Russia
      • MS in Radiophysics and Electronics, 1993
      • PhD in Biophysics, 2002
      • Dr.Sc. in Biophysics, 2017

  • 🏒 Professional Experience:

    • Full Professor, Chair of Optics and Biophotonics, Saratov State University (SSU), since 2018
    • Senior Researcher, Interdisciplinary Laboratory on Biophotonics, Tomsk State University, 2014–2018
    • Associate Professor, Chair of Optics and Biophotonics, SSU, 2003–2018
    • Assistant Professor, Chair of Optics, SSU, 2002–2003
    • Engineer, Chair of Optics, SSU, 2000–2002
    • PhD Student, Chair of Optics, SSU, 1996–2001
    • Engineer, Institute of Chemistry, SSU, 1993–1997

  • 🌟 Honors and Awards:

    • George Soros PhD student awards, 1999 and 2000
    • Post-Doctoral Fellowship Award, U.S. Civilian Research and Development Foundation for the Independent States of the Former Soviet Union (CRDF), 2003
    • Welcome Trust Award, 2005
    • Nano Research Top Papers Award, 2016

  • πŸ“š Teaching Experience:

    • Courses on Fundamentals of Photobiology, Photomedicine, Tissue Optics, Measurement Methods in Biology and Medicine, and more

  • πŸ“ Research Interests:

    • Biological and medical physics, biophotonics, biomedical optics, nanobiophotonics, OCT, optical and laser measurements, photodynamic/photothermal therapy

  • πŸ“ƒ Selected Papers:

    • Published numerous papers and reviews in peer-reviewed journals such as J. Biophotonics, J. Biomedical Optics, and others

  • πŸŽ™οΈ Professional Activities:

    • Member of editorial boards and reviewer for various scientific journals
    • Member of international conference committees including Saratov Fall Meeting

  • πŸ“˜ Book Editor:

    • Edited “Handbook of tissue optical clearing: new prospects in optical imaging,” CRC Press, 2022

  • πŸ… Special Issues:

    • Guest editor and contributor to special issues in journals and proceedings on biophotonics technologies

πŸ“ŠπŸ”¬Notable Publication:

Photothermal and photodynamic therapy of tumors with plasmonic nanoparticles: challenges and prospects

Authors: Alla B Bucharskaya, Nikolai G Khlebtsov, Boris N Khlebtsov, Galina N Maslyakova, Nikita A Navolokin, Vadim D Genin, Elina A Genina, Valery V Tuchin

Journal: Materials

Year: 2022

 

Rapid ultrasound optical clearing of human light and dark skin

  • Authors: Elina A Genina, Yury I Surkov, Isabella A Serebryakova, Alexey N Bashkatov, Valery V Tuchin, Vladimir P Zharov
  • Journal: IEEE Transactions on Medical Imaging
  • Year: 2020

 

Optical clearing of tissues: issues of antimicrobial phototherapy and drug delivery

  • Authors: Valery V Tuchin, Elina A Genina, Elena S Tuchina, Anna V Svetlakova, Yulia I Svenskaya
  • Journal: Advanced Drug Delivery Reviews
  • Year: 2021

 

Optimized skin optical clearing for optical coherence tomography monitoring of encapsulated drug delivery through the hair follicles

  • Authors: Sergey M Zaytsev, Yulia I Svenskaya, Ekaterina V Lengert, Georgy S Terentyuk, Alexey N Bashkatov, Valery V Tuchin, Elina A Genina
  • Journal: Journal of Biophotonics
  • Year: 2020

 

Glycerol effects on optical, weight and geometrical properties of skin tissue

  • Authors: Vadim D Genin, Elina A Genina, Valery V Tuchin, Alexey N Bashkatov
  • Journal: Journal of Innovative Optical Health Sciences
  • Year: 2021

Dr Jianjun Xu | Hepatobiliary Oncology and Cancer | Best Researcher Award

Posted on by Pencis

Dr Jianjun Xu | Hepatobiliary Oncology and Cancer | Best Researcher Award

Union Hospital, Tongii Medical | China

Author Profile

Scopus

Orcid id

πŸ₯ Dr. Jianjun Xu: Pioneering Hepatobiliary Oncology Specialist

πŸ‘¨β€βš•οΈ Full Name: Jianjun Xu

πŸ… Designation: Attending Doctor

🏨 Department:

  • Department of Hepatobiliary Surgery
  • Center for Liver Transplantation

πŸŽ“ Qualification: Doctor

πŸ”¬ Area of Specialization: Hepatobiliary Oncology and Cancer

πŸ’‘ Sub Division: Oncology Therapeutics and Novel Approaches

πŸ•’ Total Experience:

  • Work for 2 years
  • Doctor for 3 years
  • Master for 3 years
  • Bachelor for 5 years

 

πŸŽ“ Education

πŸ“š 2011-2016: Bachelor of Clinical Medicine, School of Medicine, Nanchang University.

πŸŽ“ 2016-2019: Master of Surgery, Tongji Medical College, Huazhong University of Science and Technology.

🏫 2019-2022: Doctor of Surgery, Tongji Medical College, Huazhong University of Science and Technology.

πŸ₯ Experience

🩺 July 2022 to Present: Attending Doctor at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Wuhan 430022, China.

πŸ”¬ Contributions to Research, Innovations, and Extension Activities On Hepatobiliary Oncology and Cancer

Throughout his tenure, Dr. Jianjun Xu has made significant contributions to Tumor Research & Development, Innovations, and Extension Activities. Actively participating in research projects, he has advanced the understanding of tumor biology, therapeutic interventions, and patient care outcomes. Leveraging his expertise in hepatobiliary malignancies, Dr. Xu collaborates with interdisciplinary teams to identify novel biomarkers, therapeutic targets, and treatment modalities, aiming to improve patient outcomes and quality of life.

Dr. Xu has also been involved in innovative initiatives to translate research findings into clinical practice. By fostering partnerships with industry stakeholders, academic institutions, and healthcare providers, he has facilitated the development and implementation of cutting-edge technologies and treatment approaches in oncology.

In addition to his research endeavors, Dr. Xu actively engages in extension activities to disseminate knowledge and promote awareness of cancer prevention, early detection, and treatment options within the community. Through educational workshops, public seminars, and outreach programs, he empowers patients, caregivers, and healthcare professionals with the necessary information and resources to combat cancer effectively. His dedication to advancing cancer research, innovation, and community outreach underscores his commitment to making a meaningful impact in the fight against cancer.

NOTABLE PUBLICATION:

Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma

Citation: 52Β  Β  Β  Β  Year: 2021

High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma

Citation: 18Β  Β  Β  Β  Year: 2022

Systemic immune-inflammation index predicts postoperative acute kidney injury in hepatocellular carcinoma patients after hepatectomy

Citation: 09Β  Β  Β  Β  Year: 2021

Laparoscopic resection of hepatic epithelioid hemangioendothelioma: report of eleven rare cases and literature review

Citation: 05Β  Β  Β  Β  Year: 2020

Light-triggered polymeric prodrug and nano-assembly for chemo-photodynamic therapy and potentiate immune checkpoint blockade immunotherapy for hepatocellular carcinoma

Citation: 02Β  Β  Β  Β  Year: 2023